Project Grant HT94252410475
Award Date
8/15/24
Completion Date
8/14/27
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
The University of Michigan will receive $702,000 under a three-year Project Grant award from the Department of the Army Medical Command to support research into new treatment strategies for ovarian cancer and PARP inhibitor-resistant tumors. The grant funding, provided through the Military Medical Research and Development program, will allow University researchers to investigate techniques for re-activating Protein Phosphatase 2A (PP2A) as a potential means of treating homologous recombination...
This federal Project Grant award, with an ID of HT94252410974, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $1,390,569.00 award supports research focused on the "THERAPEUTIC MODULATION OF THE SERINE/THREONINE PHOSPHATASE PP2A TO PREVENT RESISTANCE TO MAPK INHIBITOR THERAPY IN NSCLC", with a performance period from November 1, 2024 to October 31, 2027. The award recipient is the Regents of the University of...
The University of Michigan will receive $782,729 from the Department of the Army Medical Command under a Project Grant award through the Military Medical Research and Development program (CFDA 12.420) to improve outcomes for women with ovarian cancer. The four-year award beginning September 1, 2022 will support research to transform healthcare for Service Members and the public through innovative medical solutions for the battlefield and investigation of solutions for ovarian cancer. The...
The University of Michigan received a $925,834 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The grant will fund research into CDK12 as a context-specific tumorigenesis regulator and novel therapeutic target in castration-resistant prostate cancer. The research will be performed in Ann Arbor, Michigan over a three-year period from September 2021 through August 2024. Through the support of basic,...
This $1,248,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support the "RARE-CANCER COMMONS: A HUB FOR ACCELERATING INDIVIDUALIZED RARE CANCER THERAPY THROUGH INTEGRATION OF SINGLE-CELL AND CLINICAL GENOMICS DATA" research initiative at the University of Michigan. The project, running from November 1, 2024 to October 31, 2027, will leverage the University's extensive research capabilities to...
The University of Michigan was awarded a $900,640 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 2021 through August 2024 to target chromatin remodeling complexes in order to inhibit oncogenic androgen receptor activity in prostate cancer. Through basic, applied, and advanced biomedical research supported by this program, the University aims to...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $467,742 Project Grant to the Regents of the University of Michigan to optimize a risk stratification model for ovarian cancer. The award will support research activities from September 1, 2024 through August 31, 2026. The University of Michigan, a top public research institution, has extensive experience conducting federal research and development projects for agencies such as the...
This $924,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Wayne State University to target dual-specificity phosphatase 1 in platinum resistance in ovarian cancer. The award, which runs from July 1, 2024 to June 30, 2028, will enable Wayne State to conduct innovative scientific studies to improve treatment options and outcomes for this challenging form of cancer, which disproportionately impacts...
The University of Michigan will receive $1,169,999 under a three-year Project Grant award from the Department of the Army Medical Command to identify therapeutic vulnerabilities of bone marrow-driven recurrence of ER+ breast cancer. The award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative solutions for battlefield medicine and investigations into medical...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,178,136.00 to The Trustees of the University of Pennsylvania to conduct research on exploiting the absence of TP53 mutations in epithelial ovarian cancer using next-generation p53-stabilizing agents. The research aims to transform healthcare for military service members and the broader public by advancing innovative approaches to disease...